What's Next for Eli Lilly's COVID-19 Antibodies?
The race to develop lifesaving COVID-19 treatments recently took a surprise turn for the worse. Eli Lilly's (NYSE: LLY) COVID-19 treatment candidate, an antibody called LY-CoV555, flopped in a clinical trial with hospitalized patients.
The failure is more than a little surprising because the same treatment candidate was also part of a different study that produced positive results.
Image source: Getty Images.
Source Fool.com
